Max Healthcare Institute Limited (MAXHEALTH) — Financial Results Announcement

Investor Takeaways

Overall Tone: Positive

Key Financial Highlights

What Changed

The company reported consolidated revenue of ₹85,361 crores for FY 2025-26, reflecting a 21.5% year-on-year increase from ₹70,285 crores. Net profit rose to ₹1,07,588 lakhs, a 25.5% improvement over the previous year's ₹1,44,241 lakhs. The Board approved a final dividend of ₹2 per share and re-appointed key directors including Anil Kumar Bhatnagar. Phase-I of a new 712-bed hospital in Lucknow was greenlit with an investment of approximately ₹1,400 crores, and the registered office was shifted to Gurugram. Additionally, the company acquired a 58.28% stake in Kalinga Hospitals for ₹29,797 lakhs. Capacity utilization exceeded 75% in Q4 FY26, indicating strong demand. Revenue growth was driven by expanded hospital operations and strategic acquisitions, while profitability improved significantly year-on-year.

Peer Comparison

MAXHEALTH trades at a significantly higher P/E ratio compared to Sun Pharmaceutical and Divi's Laboratories, suggesting market expectations of higher future growth. However, its ROE and ROCE metrics are not provided in the current filing, limiting direct profitability comparison. The company's market capitalization is substantially lower than Sun Pharmaceutical but comparable to Divi's Laboratories.

Risks & Concerns

Quarterly Trend

The quarterly trend shows consistent revenue and profit growth across all four quarters, with operating profit margins remaining stable above 25%. The most recent quarter (Q3FY25) recorded the highest revenue and profit, followed by a slight dip in Q4FY24 before stabilization. The company maintained healthy margins throughout the fiscal year, indicating effective cost management alongside revenue expansion.